Orexigen Therapeutics, Inc. : OREX

All OREX Articles

70 Articles

Jon C. Ogg | Jun 12, 2014 at 8:30 AM EDT

Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More

These are the top Wall Street analyst upgrades, downgrades and initiations for Thursday, June 12, 2014. They include Apache, Apple,…

Jon C. Ogg | Jun 11, 2014 at 5:02 PM EDT

Orexigen Irony: No VIVUS Bounce

ThinkstockVIVUS Inc. (NASDAQ: VVUS) investors have a lot to be disappointed about these days. America’s ballooning waistline is reaching a…

Jon C. Ogg | Jan 27, 2014 at 8:50 AM EST

Piper Jaffray’s Seven Biotech Stocks to Buy With Huge Potential Upside

Once again, the analysts at Piper Jaffray are conducting extensive management meetings with the companies they cover. Here are the…

Trey Thoelcke | Dec 19, 2013 at 8:30 AM EST

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.

Jon C. Ogg | Oct 3, 2013 at 8:30 AM EDT

Top Analyst Upgrades and Downgrades: BlackBerry, Micron, SanDisk, VIVUS and More

Jon OggWith the government shut down and with the debt ceiling debate breathing down everyone’s neck, investors have to be…

Lee Jackson | Sep 26, 2013 at 8:15 AM EDT

Analysts See Big Upside in 10 Stocks to Buy Under $10

ThinkstockAs a rule, Wall Street brokers and financial advisors typically try to steer their clients away from stocks that trade…

Jon C. Ogg | Jun 13, 2013 at 8:15 AM EDT

Merrill Lynch Top Biotechnology Stocks to Buy for Big Gains

ThinkstockThe higher the market climbs, the harder it becomes for investors to find solid stock ideas to add or scale…

Paul Ausick | May 3, 2013 at 8:30 AM EDT

Arena Withdraws Application for Weight-Loss Drug Approval in Europe

ThinkstockDrug maker Arena Pharmaceuticals Inc. (NASDAQ: ARNA) has withdrawn its application for European regulatory approval of its weight-loss drug Belviq.…

Jon C. Ogg | Mar 28, 2013 at 8:50 AM EDT

Top Biotech-Pharma Stock Ideas With Continued Big Upside (OREX, HALO, BAX, BMRN)

ThinkstockMuch of the research coverage on Wall St. from the bulge bracket firms is concentrated on the most liquid, best…

Jon C. Ogg | Feb 25, 2013 at 5:08 PM EST

VIVUS Obesity Drug Sales Only About 60% of Expectations

ThinkstockVIVUS Inc. (NASDAQ: VVUS) reported a quarterly loss of $0.56 per share on Monday, but this was not an earnings…

Jon C. Ogg | Feb 21, 2013 at 5:20 PM EST

Europe Denies Obesity Drug Approval

ThinkstockIf you are obese in Europe, you are not about to get a little pill to take to help you change.…

Jon C. Ogg | Feb 1, 2013 at 9:04 AM EST

Positive Clinical Study Could Provide a Tailwind for Obesity Drugs (VVUS, ARNA, OREX)

ThinkstockAccording to the Centers for Disease Control (CDC), more than one-third (35.7%) of all adults in the United States are…

Jon C. Ogg | Jan 22, 2013 at 1:21 PM EST

Arena Risk: Possible Drag on All Weight-Loss Drugs

ThinkstockArena Pharmaceuticals Inc. (NASDAQ: ARNA) is posing yet one more threat to ambitious biotechs and drug-makers who are targeting the…

Jon C. Ogg | Jan 16, 2013 at 8:16 AM EST

The Obesity Drug Stock Rally Has Started (OREX, ARNA, VVUS, BAC)

ThinkstockBack in December, we took an in-depth look at what has become a crowded race in the obesity drug market.…

Jon C. Ogg | Dec 18, 2012 at 10:43 AM EST

Is There Finally a Winner in the Crowded Obesity Drug Market?

ThinkstockAccording to the Centers for Disease Control (CDC), more than one-third (35.7%) of all adults in the United States are…

1 2 3 4 5

Orexigen Therapeutics, Inc. : OREX

All OREX Articles

Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More

Orexigen Irony: No VIVUS Bounce

Piper Jaffray’s Seven Biotech Stocks to Buy With Huge Potential Upside

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Top Analyst Upgrades and Downgrades: BlackBerry, Micron, SanDisk, VIVUS and More

Analysts See Big Upside in 10 Stocks to Buy Under $10

Merrill Lynch Top Biotechnology Stocks to Buy for Big Gains

Arena Withdraws Application for Weight-Loss Drug Approval in Europe

Top Biotech-Pharma Stock Ideas With Continued Big Upside (OREX, HALO, BAX, BMRN)

VIVUS Obesity Drug Sales Only About 60% of Expectations

Europe Denies Obesity Drug Approval

Positive Clinical Study Could Provide a Tailwind for Obesity Drugs (VVUS, ARNA, OREX)

Arena Risk: Possible Drag on All Weight-Loss Drugs

The Obesity Drug Stock Rally Has Started (OREX, ARNA, VVUS, BAC)

Is There Finally a Winner in the Crowded Obesity Drug Market?

Kevin Warsh Says Good Riddance. After Powell Goes, He Wants a Transformed Fed — the Market May Not Like It

Airline Stocks Heading Into Summer 2026: Pricing Power vs Cost Pressure

How Much Do You Really Need in Treasury Bonds to Replace a $50,000 Salary With Interest

How Much Do You Really Need in Treasury Bonds to Replace a $50,000 Salary With Interest

Fed’s Rate Freeze Could Sting for Social Security Recipients

Kevin Warsh Says Good Riddance. After Powell Goes, He Wants a Transformed Fed — the Market May Not Like It

Airline Stocks Heading Into Summer 2026: Pricing Power vs Cost Pressure

Orexigen Therapeutics, Inc. : OREX

All OREX Articles

Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More

Orexigen Irony: No VIVUS Bounce

Piper Jaffray’s Seven Biotech Stocks to Buy With Huge Potential Upside

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Top Analyst Upgrades and Downgrades: BlackBerry, Micron, SanDisk, VIVUS and More

Analysts See Big Upside in 10 Stocks to Buy Under $10

Merrill Lynch Top Biotechnology Stocks to Buy for Big Gains

Arena Withdraws Application for Weight-Loss Drug Approval in Europe

Top Biotech-Pharma Stock Ideas With Continued Big Upside (OREX, HALO, BAX, BMRN)

VIVUS Obesity Drug Sales Only About 60% of Expectations

Europe Denies Obesity Drug Approval

Positive Clinical Study Could Provide a Tailwind for Obesity Drugs (VVUS, ARNA, OREX)

Arena Risk: Possible Drag on All Weight-Loss Drugs

The Obesity Drug Stock Rally Has Started (OREX, ARNA, VVUS, BAC)

Is There Finally a Winner in the Crowded Obesity Drug Market?

Kevin Warsh Says Good Riddance. After Powell Goes, He Wants a Transformed Fed — the Market May Not Like It

Airline Stocks Heading Into Summer 2026: Pricing Power vs Cost Pressure

How Much Do You Really Need in Treasury Bonds to Replace a $50,000 Salary With Interest

Featured Reads

How Much Do You Really Need in Treasury Bonds to Replace a $50,000 Salary With Interest

Fed’s Rate Freeze Could Sting for Social Security Recipients